James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Lowe’s Companies, Inc. (LOW), Chico’s FAS, Inc. (CHS) and Tiffany & Co. (TIF) Are 3 of Today’s Worst Stocks

Tiffany (TIF), Lowe's Companies (LOW) and Chico's FAS (CHS) shareholders couldn't wait for Wednesday's trading to come to a close.

Under Armour Inc (UA) Stock Is Too Out of Shape to Bother With

Under Armour stock teased investors with a big gain after its last earnings report, but UA has given almost all of that gain back.

Apple Inc.’s Next Great Driver? India! (AAPL)

Apple isn't tough to own in the first place, but if its Indian plans pan out as expected, AAPL stock holders will have plenty to smile about.

Why Alexion Pharmaceuticals, Inc. (ALXN), Xilinx, Inc. (XLNX) and AutoZone, Inc. (AZO) Are 3 of Today’s Worst Stocks

Xilinx (XLNX), AutoZone (AZO) and Alexion Pharmaceuticals (ALXN) shareholders had to ride out a very rough patch today.

Snap: 3 Things You Should Have Noticed Before the IPO

SNAP stock hasn't been the performer it was supposed to be, though in retrospect its lackluster results shouldn't be all that surprising.